

(Securities Code 7702)

JMS CO.,LTD.

Financial Statements

for the 1st Quarter of Fiscal Year Ending March 31, 2026

(From Apr. 1, 2025 to Jun. 30, 2025)

Summary of consolidated results

August 8, 2025

Summary of Financial Results

Consolidated

Decrease in sales
Decrease in profit

Net sales
Operating profit

15,546 million yen ((630) million yen)
(176) million yen ((219) million yen)

Sales : Sales decreased due to a decline in sales of mainstay products overseas, despite domestic growth in the Oncological Therapy and Nutrition businesses.

Profit : Despite reductions in manufacturing expenses, income decreased due to a decline in gross profit and an increase in selling expenses associated with lower sales of overseas main products.

Sales by Business Segment

Infusion & Enteral Nutrition : Sales of Closed Drug Mixing/Infusion Systems remained strong and Dysphagia-related products grew due to increased demand, but overall sales were flat due to a decrease in Medical Gloves.

Blood Management and Cell Therapy : Revenue decreased due to a decrease in Apheresis Kits for North America, despite continued growth in Blood Bags.

Sales by Region

Asia : Decrease in sales of Blood Bags and Hemodialysis Machines for China.


Europe: Sales increased due to steady demand for AV Fistula Needles and Blood Bags.

Highlights in Business Results


(unit: JPY million)

	Apr. - Jun. 2024 Results	Apr. - Jun. 2025 Results	Year-over-Year	
			Diff.	%
Net sales	16,177	15,546	(630)	(3.9)%
Operating profit	42	(176)	(219)	—
Ordinary profit	194	(283)	(478)	—
Profit attributable to owners of parent	(92)	(459)	(367)	—


Net sales




Operating profit



Ordinary profit



Profit attributable to owners of parent



Summary by segment (geographical area)

[Japan] Sales decreased due to a decline in sales of Hemodialysis Machines and Acute Blood Purification Systems for China, despite continued growth in Closed Drug Mixing/Infusion Systems and Dysphagia-related products. Income decreased due to an increase in selling, general and administrative expenses, in addition to higher labor and electricity costs.

[Germany] Sales of AV Fistula Needles for Europe and Blood Bags remained strong, resulting in increased revenue and profits.

(unit: JPY million)

		Apr. - Jun. 2024	Apr. - Jun. 2025	Year-over-Year	
				Diff.	%
Japan	Sales	10,705	10,545	(159)	(1.5)%
	Ordinary profit	252	121	(131)	(52.0)%
Singapore※	Sales	5,738	5,639	(99)	(1.7)%
	Ordinary profit	40	(248)	(288)	—
China	Sales	1,010	922	(87)	(8.7)%
	Ordinary profit	(36)	1	38	—
Philippines	Sales	911	839	(71)	(7.8)%
	Ordinary profit	(149)	(150)	(0)	—
Germany	Sales	938	1,080	142	15.1%
	Ordinary profit	74	129	54	73.9%
Others※	Sales	1,152	1,483	331	28.8%
	Ordinary profit	(12)	(43)	(30)	—

※Singapore : This segment includes Indonesian subsidiary.

※Others : This segment includes business activity of subsidiaries in Japan, United States, South Korea , Thailand and Part of China.

(unit: JPY million)

Infusion & Nutrition

5,839 5,834

■ Apr. - Jun. 2024 ■ Apr. - Jun. 2025



Net sales


Sales remained flat as growth in Closed Drug Mixing/Infusion Systems and Dysphagia-related products was offset by a decline in medical glove sales.



Dialysis

4,810 4,865

■ Apr. - Jun. 2024 ■ Apr. - Jun. 2025



Net sales


Despite strong AV Fistula Needles sales, flat results due to decreased sales of Hemodialysis Machines for China.



Cardiovascular

1,298 1,305

■ Apr. - Jun. 2024 ■ Apr. - Jun. 2025



Net sales

Hemoconcentrators increased, but Blood Purification Systems decreased and remained flat.




Blood Management & Cell Therapy

3,920

3,147

■ Apr. - Jun. 2024 ■ Apr. - Jun. 2025



Net sales

Revenue decreased due to a significant decrease in Apheresis Kits for North America, despite continued growth in Blood Bags.




Sales by Region (Customer's Location)

Europe saw strong growth of AV Fistula Needles sales, while domestic demand for Closed Drug Mixing/Infusion Systems and Dysphagia-related products remained robust. However, overall sales declined due to lower sales of Hemodialysis Machines for China and Apheresis Kits for North America.

(unit: JPY million)

	Apr. - Jun. 2024	Apr. - Jun. 2025	Year-over-Year		Sales composition
			Diff.	%	
Japan	9,248	9,580	332	3.6%	61.6%
Asia	3,200	2,107	(1,093)	(34.2)%	13.6%
North America	1,923	1,135	(787)	(40.9)%	7.3%
Europe	1,408	2,079	670	47.6%	13.4%
Others	395	643	248	62.8%	4.1%




Ordinary profit : Compared with the previous year

The decrease in gross profit due to lower sales of Apheresis Kits and Blood Bags, which are our main overseas products, had a significant impact.

Despite the effects of reductions in manufacturing expenses and equity in net income of affiliated companies, ordinary loss was recorded due to an increase in selling, general and administrative expenses and foreign exchange losses resulting from unfavorable exchange rates.

(unit: JPY million)

*The underlined figures exclude impact of exchange rate.



Exchange Rate (average during period)

(unit: JPY)

	US Dollar	Euro	Singapore Dollar
Apr. - Jun. 2024	155.88	161.31	115.21
Apr. - Jun. 2025	144.59	160.50	111.11

Forecast for FYE Mar. 2026

The earnings forecast has not been changed since its announcement on May 9, 2025.

(unit: JPY million)

	FYE Mar. 2025 Result	FYE Mar. 2026 Forecast	Year-over-Year
Net sales	69,749	68,000	(2.5)%
Operating profit	872	900	3.1%
Ordinary profit	514	600	16.5%
Profit attributable to owners of parent	89	200	123.4%

* Exchange rate for the forecast: 1USD=140yen, 1EUR=155yen, 1SGD=106yen.

Sales :	In Japan, we will expand sales of Closed Drug Mixing/Infusion Systems and Dysphagia-related products, which are growth areas. Overseas, we will steadily capture demand for AV Fistula Needles and Blood Bags, which are expected to grow.
Profit :	Profit recovery is expected through expanded sales in growth areas in Japan and overseas, initiatives in new business fields, and the promotion of appropriate price transfers and cost reductions.



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.